Cambridge Investment Research Advisors
ALXN

Cambridge Investment Research Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-14,573
Closed -$2.68M – 3266
2021
Q2 		$2.68M Buy
14,573
+410
+3% +$70.4K 0.01% 959
2021
Q1 		$2.17M Buy
14,163
+3,787
+36% +$586K 0.01% 966
2020
Q4 		$1.62M Buy
10,376
+692
+7% +$88.9K 0.01% 1043
2020
Q3 		$1.11M Sell
9,684
-280
-3% -$30.2K 0.01% 1125
2020
Q2 		$1.12M Sell
9,964
-806
-7% -$85.6K 0.01% 1062
2020
Q1 		$967K Buy
10,770
+1,742
+19% +$171K 0.01% 995
2019
Q4 		$976K Sell
9,028
-310
-3% -$33.2K 0.01% 1161
2019
Q3 		$915K Buy
9,338
+1,834
+24% +$207K 0.01% 1122
2019
Q2 		$983K Buy
7,504
+731
+11% +$94.2K 0.01% 1033
2019
Q1 		$916K Buy
6,773
+4,069
+150% +$506K 0.01% 1079
2018
Q4 		$263K Sell
2,704
-313
-10% -$37K ﹤0.01% 1746
2018
Q3 		$419K Buy
3,017
+722
+31% +$90.6K ﹤0.01% 1551
2018
Q2 		$285K Sell
2,295
-13
-0.6% -$1.52K ﹤0.01% 1765
2018
Q1 		$257K Sell
2,308
-1,158
-33% -$138K ﹤0.01% 1786
2017
Q4 		$414K Sell
3,466
-1,094
-24% -$133K ﹤0.01% 1434
2017
Q3 		$640K Sell
4,560
-1,002
-18% -$136K 0.01% 1098
2017
Q2 		$677K Buy
+5,562
New +$647K 0.01% 1018
2016
Q4 		– Sell
-3,416
Closed -$419K – 1838
2016
Q3 		$419K Buy
+3,416
New +$440K 0.01% 1132
2016
Q2 		– Sell
-3,893
Closed -$542K – 1695
2016
Q1 		$542K Sell
3,893
-777
-17% -$114K 0.01% 851
2015
Q4 		$891K Buy
+4,670
New +$816K 0.02% 592
2015
Q3 		– Sell
-3,227
Closed -$583K – 1613
2015
Q2 		$583K Sell
3,227
-114
-3% -$19.7K 0.02% 736
2015
Q1 		$579K Buy
3,341
+79
+2% +$14.3K 0.02% 718
2014
Q4 		$604K Buy
3,262
+60
+2% +$11.1K 0.02% 686
2014
Q3 		$531K Buy
3,202
+210
+7% +$34.5K 0.02% 798
2014
Q2 		$468K Buy
2,992
+30
+1% +$4.74K 0.02% 784
2014
Q1 		$451K Sell
2,962
-1,307
-31% -$208K 0.02% 759
2013
Q4 		$567K Sell
4,269
-1,001
-19% -$120K 0.02% 603
2013
Q3 		$612K Sell
5,270
-9,798
-65% -$1.07M 0.03% 536
2013
Q2 		$1.39M Buy
+15,068
New +$1.45M 0.07% 251

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Cambridge Investment Research Advisors's ALXN Position: Q3 2021 in Review

Cambridge Investment Research Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 14,573 shares — an estimated $2.68M sold.

Cambridge Investment Research Advisors first reported a position in ALXN in Q2 2013 and held it in 29 quarters. The position peaked at $2.68M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Cambridge Investment Research Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 14,573 Alexion Pharmaceuticals shares in Q3 2021, an estimated $2.68M.
  • Cambridge Investment Research Advisors first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 29 quarters.
  • Cambridge Investment Research Advisors's Alexion Pharmaceuticals position peaked at $2.68M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2021, filed 2 Nov 2021.